Lalistat 1

Lalistat 1 is a potent, selective, and competitive inhibitor of lysosomal acid lipase (LAL) and against purified human LAL (phLAL) with an IC50 of 68 nM. Lalistat 1 is a inhibitor of immunoglobulin A1 protease (IgA1P) proteases for H. influenzae, has less effects on other serine hydrolases (trypsin or β-lactamase, etc.) . Lalistat 1 can be used for the research of niemann-pick type C (NPC) disease[2].

Product Specifications

CAS Number

[501104-16-1]

Product Name Alternative

AM152

UNSPSC

12352005

Hazard Statement

H302, H312, H315, H319, H332, H335

Target

Bacterial; Beta-lactamase

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/lalistat-1.html

Purity

99.75

Solubility

DMSO : 20 mg/mL (ultrasonic; warming)

Smiles

O=C(N1CCOCC1)OC2=NSN=C2N3CCCCC3

Molecular Formula

C12H18N4O3S

Molecular Weight

298.37

Precautions

H302, H312, H315, H319, H332, H335

References & Citations

[1]Anton I Rosenbaum , et al. Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann-Pick type C disease therapeutics. J Med Chem . 2010 Jul 22;53 (14) :5281-9.|[2]Livia Shehaj, et al. Small-Molecule Inhibitors of Haemophilus influenzae IgA1 Protease.ACS Infect Dis. 2019 Jul 12;5 (7) :1129-1138.